In a press release on 9 September, the MHRA confirmed that COVID-19 vaccines made by Pfizer and AstraZeneca might be used ‘as protected and efficient booster doses’.
The replace from the regulator comes after well being and social care secretary Sajid Javid mentioned this week that he was ‘assured’ a booster marketing campaign would begin this month, and that he anticipated ultimate recommendation from the Joint Committee on Vaccination and Immunisation (JCVI) ‘inside days’.
The scope of a possible booster marketing campaign stays unclear, nevertheless. Interim recommendation from the JCVI in June urged booster jabs might be rolled out to individuals aged over 70, those that are clinically susceptible and well being and care workers alongside a flu jab from 1 September.
The interim recommendation urged the marketing campaign might then widen to cowl all individuals aged over 50, 16- to 59-year-olds in flu or COVID-19 at-risk teams and family contacts of some at-risk sufferers.
Nonetheless, later feedback from a JCVI member urged booster jabs might solely be mandatory for a a lot smaller group of individuals.
MHRA chief government Dr June Raine mentioned: ‘We’re dedicated to getting protected and efficient COVID-19 vaccines to the UK public. This implies guaranteeing that current COVID-19 vaccines can proceed for use in the simplest method doable.
‘We all know that an individual’s immunity might decline over time after their first vaccine course. I’m happy to verify that the COVID-19 vaccines made by Pfizer and AstraZeneca can be utilized as protected and efficient booster doses.
‘This is a vital regulatory change because it provides additional choices for the vaccination programme, which has saved 1000’s of lives to this point. It should now be for the JVCI to advise on whether or not booster jabs will probably be given and in that case, which vaccines needs to be used.’
The MHRA mentioned its choice to approve use of the vaccines for a booster marketing campaign adopted ‘a cautious evaluation of obtainable knowledge on security and effectiveness of booster or supplementary vaccine doses by the MHRA and the unbiased Fee on Human Medicines (CHM).
The JCVI has already backed a 3rd dose of COVID-19 vaccine for sufferers with extreme immunosuppression on the time of their first or second dose. Nonetheless, the committee was clear this needs to be thought-about a part of the first vaccination schedule for individuals on this group, and was not a part of the booster marketing campaign.
The UK’s 4 chief medical officers are additionally contemplating whether or not to again COVID-19 vaccination for youngsters aged 12-15, after the JCVI mentioned advantages ‘marginally outweigh’ dangers for this group, however stopped in need of recommending a rollout.